Ivacaftor (VX-770) has been approved for marketing in Europe and the USA for CF patients carrying the G551D mutation (and the other mutations recently added [33]) as the first drug targeting the actual CFTR dysfunction [34]. The gene discussed is CFTR; the disease is cystic fibrosis.